Related Experiment Video
Updated: Feb 20, 2026
09:31
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
9.7K
Biomarkers in mesothelioma.
David T Arnold1, Nick A Maskell1
1Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, UK.
Annals of Clinical Biochemistry
|October 24, 2017
Summary
Biomarkers for mesothelioma diagnosis and monitoring are under investigation. While soluble mesothelin shows potential for tracking disease progression, novel DNA and mRNA biomarkers require further clinical evaluation.
Area of Science:
- Oncology
- Biomarker Research
- Cancer Diagnostics
Background:
- Mesothelioma, an aggressive cancer of pleural and peritoneal cells, presents diagnostic and monitoring challenges.
- Existing diagnostic pathways lack specific biomarkers, and radiological assessments have limitations.
- The development of novel treatments necessitates reliable serum/plasma biomarkers for monitoring disease progression.
Purpose of the Study:
- To review the current literature on biomarkers for mesothelioma diagnosis and monitoring.
- To evaluate the potential utility of existing and novel biomarkers in clinical practice.
- To highlight the limitations and future directions in mesothelioma biomarker research.
Main Methods:
- Comprehensive literature review of studies on mesothelioma biomarkers.
- Analysis of research focusing on soluble glycoproteins (e.g., soluble mesothelin, osteopontin, fibulin-3, VEGF).
- Evaluation of emerging DNA and mRNA biomarkers from discovery cohorts.
Main Results:
- Soluble mesothelin, while not a standalone diagnostic, can inform about disease progression and survival through serial measurements.
- Elevated levels of osteopontin, fibulin-3, and vascular endothelial growth factor correlate with poor prognosis.
- Numerous DNA and mRNA biomarkers show promise but lack prospective clinical validation.
Conclusions:
- Biomarkers are crucial for improving mesothelioma diagnosis and monitoring.
- Soluble mesothelin and other glycoproteins offer prognostic information.
- Further prospective studies are needed to validate novel DNA and mRNA biomarkers for clinical application.
